145 related articles for article (PubMed ID: 38590456)
1. Spurious Hyperphosphatemia in Two Children With End-Stage Renal Disease: A Case Report.
Ahmed FS; Begum M; AlSharhan MA
Cureus; 2024 Mar; 16(3):e55818. PubMed ID: 38590456
[TBL] [Abstract][Full Text] [Related]
2. Spurious Hyperphosphatemia in a Patient with Chronic Kidney Disease - a Rare Case of Alteplase Contamination.
Khan ZUN; Ahmed S; Siddiqui A; Siddiqui I
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623682
[TBL] [Abstract][Full Text] [Related]
3. Spurious hyperphosphatemia in a patient with alteplase-locked central venous catheter.
Cachat F; Bardy D; Durussel C; Di Paolo E
Pediatr Nephrol; 2006 Feb; 21(2):301-2. PubMed ID: 16328539
[TBL] [Abstract][Full Text] [Related]
4. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
5. Alteplase as hemodialysis catheter locking solution and spurious hyperphosphatemia.
Sombolos K; Bamichas G; Hatsiou V; Fragidis S; Rizos A; Natse T; Fytili C
J Vasc Access; 2011; 12(3):269. PubMed ID: 21218384
[No Abstract] [Full Text] [Related]
6. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia.
Savica V; Calò LA; Monardo P; Santoro D; Mallamace A; Muraca U; Bellinghieri G
J Ren Nutr; 2009 Jan; 19(1):69-72. PubMed ID: 19121775
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Cost of Weekly Recombinant Tissue Plasminogen Activator Hemodialysis Catheter Locking Solution.
Hemmelgarn BR; Manns BJ; Soroka SD; Levin A; MacRae J; Tennankore K; Wilson JS; Weaver RG; Ravani P; Quinn RR; Tonelli M; Kiaii M; Mossop P; Scott-Douglas N
Clin J Am Soc Nephrol; 2018 Mar; 13(3):429-435. PubMed ID: 29335321
[TBL] [Abstract][Full Text] [Related]
8. Occluded Tunneled Venous Catheter in Hemodialysis Patients: Risk Factors and Efficacy of Alteplase.
Ponce D; Mendes M; Silva T; Oliveira R
Artif Organs; 2015 Sep; 39(9):741-7. PubMed ID: 25894244
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis.
El Borolossy R; El Wakeel LM; El Hakim I; Sabri N
Pediatr Nephrol; 2016 Feb; 31(2):289-96. PubMed ID: 26420678
[TBL] [Abstract][Full Text] [Related]
10. The impact of catheter-restricted filling with cefotaxime and heparin on the lifespan of temporary hemodialysis catheters: a case controlled study.
Saxena AK; Panhotra BR
J Nephrol; 2005; 18(6):755-63. PubMed ID: 16358235
[TBL] [Abstract][Full Text] [Related]
11. Prevention of catheter lumen occlusion with rT-PA versus heparin (Pre-CLOT): study protocol of a randomized trial [ISRCTN35253449].
Hemmelgarn BR; Moist L; Pilkey RM; Lok C; Dorval M; Tam PY; Berall MJ; LeBlanc M; Toffelmire EB; Manns BJ; Scott-Douglas N;
BMC Nephrol; 2006 Apr; 7():8. PubMed ID: 16608513
[TBL] [Abstract][Full Text] [Related]
12. Hyperphosphatemia and its relationship with blood pressure, vasoconstriction, and endothelial cell dysfunction in hypertensive hemodialysis patients.
Jung J; Jeon-Slaughter H; Nguyen H; Patel J; Sambandam KK; Shastri S; Van Buren PN
BMC Nephrol; 2022 Aug; 23(1):291. PubMed ID: 35999520
[TBL] [Abstract][Full Text] [Related]
13. Effect of Phosphate-Specific Diet Therapy on Phosphate Levels in Adults Undergoing Maintenance Hemodialysis: A Systematic Review and Meta-Analysis.
St-Jules DE; Rozga MR; Handu D; Carrero JJ
Clin J Am Soc Nephrol; 2020 Dec; 16(1):107-120. PubMed ID: 33380474
[TBL] [Abstract][Full Text] [Related]
14. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator.
Hemmelgarn BR; Moist LM; Lok CE; Tonelli M; Manns BJ; Holden RM; LeBlanc M; Faris P; Barre P; Zhang J; Scott-Douglas N;
N Engl J Med; 2011 Jan; 364(4):303-12. PubMed ID: 21268722
[TBL] [Abstract][Full Text] [Related]
15. [REIN Report 2011--summary].
Couchoud C; Lassalle M; Jacquelinet C
Nephrol Ther; 2013 Sep; 9 Suppl 1():S3-6. PubMed ID: 24119584
[TBL] [Abstract][Full Text] [Related]
16. Predialysis nephrology care amongst Palestinian hemodialysis patients and its impact on initial vascular access type.
Atieh AS; Shamasneh AO; Hamadah A; Gharaibeh KA
Ren Fail; 2020 Nov; 42(1):200-206. PubMed ID: 32506996
[TBL] [Abstract][Full Text] [Related]
17. Interventions for treating catheter-related bloodstream infections in people receiving maintenance haemodialysis.
Almeida BM; Moreno DH; Vasconcelos V; Cacione DG
Cochrane Database Syst Rev; 2022 Apr; 4(4):CD013554. PubMed ID: 35363884
[TBL] [Abstract][Full Text] [Related]
18. Cathasept Line Lock and Microbial Colonization of Tunneled Hemodialysis Catheters: A Multicenter Randomized Controlled Trial.
Kanaa M; Wright MJ; Akbani H; Laboi P; Bhandari S; Sandoe JA
Am J Kidney Dis; 2015 Dec; 66(6):1015-23. PubMed ID: 26141306
[TBL] [Abstract][Full Text] [Related]
19. Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia.
Savica V; Calò LA; Caldarera R; Cavaleri A; Granata A; Santoro D; Savica R; Muraca U; Mallamace A; Bellinghieri G
Nephron Physiol; 2007; 105(3):p52-5. PubMed ID: 17220638
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
